Study guide
13.2 ASCCP Risk-Based Management & Breast Cancer Screening
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
13.2 ASCCP Risk-Based Management & Breast Cancer Screening
Key Takeaways Explain This Topic AI
An immediate CIN 3 or worse risk of 4 percent or greater is the colposcopy threshold, while 60 percent or greater favors expedited treatment without confirmatory biopsy.
Atypical glandular cells require colposcopy plus endocervical curettage at all ages, with endometrial biopsy added at 35 or older or with bleeding or risk factors.
USPSTF now recommends biennial screening mammography from age 40 through 74 for average-risk women.
Structured monthly breast self-examination does not reduce mortality and doubles benign biopsies, so breast self-awareness is taught instead.
Annual MRI plus mammography beginning at age 25 to 30 is recommended for a calculated lifetime risk of 20 percent or higher, BRCA carriers, and prior chest radiation between ages 10 and 30.
Last updated: September 2026
ASCCP Risk-Based Management Consensus Guidelines
In 2019, the American Society for Colposcopy and Cervical Pathology (ASCCP) transitioned from rigid result-based algorithms to risk-based management guidelines . Management is determined by calculating the patient's estimated risk of harboring high-grade cervical precancer ( CIN 3+ , including CIN 3, AIS, and invasive cancer), combining current screening test results with prior screening history.
Clinical Action Thresholds for CIN 3+ Risk
Immediate Risk ≥60% (Expedited Treatment Threshold): Expedited treatment (loop electrosurgical excision procedure [LEEP] or cold knife conization) without prior confirmatory colposcopic biopsy is preferred; diagnostic colposcopy with biopsy is acceptable. (Expedited treatment is also acceptable for immediate risks between 25% and 59%).
Immediate Risk ≥4.0% (Colposcopy Threshold): Colposcopic examination with directed cervical biopsies and endocervical sampling is mandatory.
Immediate Risk <4.0% (Surveillance Thresholds):
5-Year Risk 0.55% to 3.9%: 1-year surveillance interval (repeat co-testing in 12 months).
5-Year Risk 0.15% to 0.54%: 3-year surveillance interval (repeat co-testing in 3 years).
5-Year Risk <0.15%: 5-year surveillance interval (return to routine 5-year screening).
- Management of Specific Cytologic & HPV Abnormalities ASCCP Management of Common Cytologic Abnormalities
- ├── ASC-US (Atypical Squamous Cells of Undetermined Significance)
- │ ├── Reflex hrHPV Negative ──> Repeat Co-testing or Cytology in 3 Years
- │ └── Reflex hrHPV Positive ──> Immediate Risk ≥4% ──> Perform Colposcopy
- │ └── (Special exception: Age 21-24 ──> Repeat Cytology at 12 Months)
- ├── LSIL (Low-Grade Squamous Intraepithelial Lesion)
- │ ├── Age ≥25 with hrHPV Positive or Unknown ──> Perform Colposcopy
- │ ├── Age ≥25 with hrHPV Negative Co-test ──> Repeat Co-testing in 1 Year
- │ └── Age 21-24 ──> Repeat Cytology at 12 Months (avoid colposcopy)
- ├── HSIL (High-Grade Squamous Intraepithelial Lesion)
- │ ├── Age ≥25 (Non-pregnant) ──> Expedited Treatment (LEEP) OR Colposcopy
- │ └── Age 21-24 or Pregnant ──> Colposcopy Mandatory (NO immediate LEEP)
- └── AGC (Atypical Glandular Cells)
- └── ALL Ages ──> Colposcopy + Endocervical Curettage (ECC) MANDATORY
- └── If Age ≥35 (or <35 with AUB/risk factors) ──> ADD Endometrial Biopsy (EMB)
- Colposcopy Technique & Transformation Zone
Colposcopy utilizes binocular magnification and 3% to 5% acetic acid solution (which dehydrates cellular cytoplasm, causing abnormal dysplastic cells with high nuclear-to-cytoplasmic ratios to reflect light as acetowhite epithelium ) and Lugol's iodine (Schiller test; normal glycogen-rich squamous epithelium stains dark mahogany brown, whereas dysplastic glycogen-depleted cells remain unstained/yellow).
Transformation Zone (TZ): The critical area between the original squamocolumnar junction (SCJ) and the new SCJ where squamous metaplasia occurs and >90% of cervical neoplasms arise.
Endocervical Curettage (ECC): Mandatory when the transformation zone is not fully visualized (Type 3 TZ), in evaluation of atypical glandular cells (AGC), or when excisional treatment is being planned.
Breast Cancer Screening & Breast Health Awareness
Breast cancer is the most frequently diagnosed non-skin malignancy and the second leading cause of cancer mortality among women in the United States. Early detection via screening mammography reduces breast cancer mortality by identifying asymptomatic, localized tumors at a curable stage.
USPSTF Breast Cancer Screening Guidelines (Average Risk)
Biennial Screening Mammography for Ages 40 to 74 Years: In 2024, the USPSTF formally updated its breast cancer screening guidelines, lowering the recommended start age from 50 to age 40 years . All average-risk women should undergo biennial (every 2 years) screening mammography from age 40 through 74 years (Grade B recommendation).
Ages ≥75 Years: Current evidence is insufficient (Grade I statement) to assess the balance of benefits and harms of screening mammography in women aged 75 and older; clinical decisions should incorporate life expectancy (≥10 years), comorbidities, and patient preferences.
Screening Modality: Digital breast tomosynthesis (3D mammography) or conventional digital mammography (2D). Supplemental screening with breast ultrasound or MRI in women with dense breast tissue without other risk factors remains an area of insufficient evidence (Grade I).
Clinical Breast Examination (CBE) & Breast Self-Awareness
Routine Screening CBE: The USPSTF concludes that current evidence is insufficient to recommend for or against routine clinical breast examination in average-risk, asymptomatic women. ACOG suggests that clinical breast examination may be offered every 1 to 3 years for women aged 25 to 39, and annually for women aged 40 and older, as part of a shared decision-making discussion.
Breast Self-Examination (BSE) vs. Breast Self-Awareness: Randomized clinical trials (such as the Shanghai trial) demonstrate that teaching formal, structured, monthly breast self-examination does not reduce breast cancer mortality but doubles the rate of benign breast biopsies and physician visits. Therefore, professional organizations do NOT recommend teaching routine structured BSE. Instead, nurse-midwives promote breast self-awareness —educating women to understand the normal appearance and texture of their breasts and to report any new, persistent changes promptly.
Red Flag Symptoms Warranting Diagnostic Evaluation: A new discrete, firm, solitary dominant mass; spontaneous, unilateral, single-duct bloody or clear serosanguinous nipple discharge; skin dimpling or retraction; nipple inversion of recent onset; erythema, edema, or "peau d'orange" (suggestive of inflammatory breast cancer); and persistent axillary or supraclavicular lymphadenopathy.
High-Risk Breast Cancer Surveillance
Women with elevated breast cancer risk require enhanced surveillance beginning at a much younger age:
Risk Assessment Tools: The Gail Model, Tyrer-Cuzick (IBIS) model, and BRCAPRO quantify lifetime breast cancer risk based on age, reproductive history, prior atypical biopsies (lobular carcinoma in situ [LCIS] or atypical ductal hyperplasia [ADH]), and pedigree.
Annual Screening MRI + Annual Mammography: Recommended for women with a calculated lifetime risk ≥20% , individuals with documented BRCA1 or BRCA2 genetic mutations, first-degree relatives of BRCA carriers who are untested, or women with a history of therapeutic mantle radiation to the chest between ages 10 and 30. Surveillance begins at age 25 to 30 years (or 10 years earlier than the youngest affected first-degree relative), alternating breast MRI and mammography every 6 months.